HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- cyclopropyl- 1- (4- (6- ((1,1- dioxidothiomorpholino)methyl)- 5- fluoropyridin- 2- yl)benzyl)imidazolidine- 2,4- dione hydrochloride

structure in first source

Also Known As:

LEI-101

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Imidazolidines: 39
        3-cyclopropyl-1-(4-(6-((1,1-dioxidothiomorpholino)methyl)-5-fluoropyridin-2-yl)benzyl)imidazolidine-2,4-dione hydrochloride: 1
  - Oxazines: 9
    - Morpholines: 6
      - 3-cyclopropyl-1-(4-(6-((1,1-dioxidothiomorpholino)methyl)-5-fluoropyridin-2-yl)benzyl)imidazolidine-2,4-dione hydrochloride: 1

Experts

1.	Baggelaar, Marc: 1 article (02/2016)
2.	Cao, Zongxian: 1 article (02/2016)
3.	Cinar, Resat: 1 article (02/2016)
4.	Erdelyi, Katalin: 1 article (02/2016)
5.	Fezza, Filomena: 1 article (02/2016)
6.	Hansen, Thomas: 1 article (02/2016)
7.	Heitman, Laura: 1 article (02/2016)
8.	Ignatowska-Janlowska, Bogna: 1 article (02/2016)
9.	Kunos, George: 1 article (02/2016)
10.	Lichtman, Aron: 1 article (02/2016)

Related Diseases

1.	Kidney Diseases (Kidney Disease) 02/01/2016 - "These results indicate that LEI-101 is a selective, largely peripherally restricted, orally available CB2 receptor agonist with therapeutic potential in diseases that are associated with inflammation and/or oxidative stress, including kidney disease."
2.	Inflammation (Inflammations) 02/01/2016 - "These results indicate that LEI-101 is a selective, largely peripherally restricted, orally available CB2 receptor agonist with therapeutic potential in diseases that are associated with inflammation and/or oxidative stress, including kidney disease."

Related Drugs and Biologics

1.	CB2 Cannabinoid Receptor